Published in:
01-09-2008 | Short Communication
The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality
Published in: Osteoporosis International | Issue 9/2008
Login to get accessAbstract
Summary
Anti-resorptive strategies may affect bone collagen maturation differently depending on the mode of action. Orally administrated calcitonin resulted in a dose dependent inhibition of bone resorption but did not change bone collagen maturation. This may reflect aspects of bone quality.
Introduction
The aim of the present study was to evaluate the effect of oral calcitonin on bone collagen maturation measured as the ratio between the degradation products of newly synthesized C-telopeptides of type I collagen (ααCTX) and mature isomerized ββCTX in postmenopausal women.
Methods
Participants were from a phase II study. A total of 168 postmenopausal women were included and treated with placebo, 0.15, 0.4, 1, or 2.5 mg calcitonin daily. The non-isomerized ααCTX and isomerized ββCTX were measured in 24-hour urine samples obtained at baseline, and after 1 day, 1 month and 3 months of therapy.
Results
Calcitonin, significantly and dose-dependently inhibited bone resorption by up to 50% as measured by ααCTX and isomerized ββCTX. Bone collagen maturation measured as the ratio between ααCTX and ββCTX remained unchanged during treatment with calcitonin.
Conclusions
Calcitonin dose-dependently and significantly reduced both ααCTX to ββCTX levels in urine without affecting the ααCTX to ββCTX ratio. This is in direct contrast to other anti-resorptive therapies, in which strong treatment-dependent effect on the endogenous age profile of bone has been observed. These data highlight that even though the treatments may have comparable effects on BMD, endogenous bone composition, which may be associated to bone quality, is strongly affected by the type of intervention, in which calcitonin display highly divergent effects from that of other anti-resorptives.